| Literature DB >> 27533014 |
Deshapriya S Karunarathne1, Joshua M Horne-Debets1, Johnny X Huang2, Rebecca Faleiro1, Chiuan Yee Leow1, Fiona Amante1, Thomas S Watkins1, John J Miles1, Patrick J Dwyer3, Katryn J Stacey4, Michael Yarski5, Chek Meng Poh6, Jason S Lee1, Matthew A Cooper2, Laurent Rénia6, Derek Richard7, James S McCarthy1, Arlene H Sharpe8, Michelle N Wykes9.
Abstract
Many pathogens, including Plasmodium spp., exploit the interaction of programmed death-1 (PD-1) with PD-1-ligand-1 (PD-L1) to "deactivate" T cell functions, but the role of PD-L2 remains unclear. We studied malarial infections to understand the contribution of PD-L2 to immunity. Here we have shown that higher PD-L2 expression on blood dendritic cells, from Plasmodium falciparum-infected individuals, correlated with lower parasitemia. Mechanistic studies in mice showed that PD-L2 was indispensable for establishing effective CD4(+) T cell immunity against malaria, because it not only inhibited PD-L1 to PD-1 activity but also increased CD3 and inducible co-stimulator (ICOS) expression on T cells. Importantly, administration of soluble multimeric PD-L2 to mice with lethal malaria was sufficient to dramatically improve immunity and survival. These studies show immuno-regulation by PD-L2, which has the potential to be translated into an effective treatment for malaria and other diseases where T cell immunity is ineffective or short-lived due to PD-1-mediated signaling.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27533014 DOI: 10.1016/j.immuni.2016.07.017
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745